Biochemistry and pharmacology of the human multidrug resistance gene product, ABCG2

Journal of Central South University (Medical Sciences)

Volumn 32, Issue 4, 2007, Pages 531-541

  Zhang, Jian Ting ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ABC transporter; ABCG2; BCRP; Drug resistance; Multidrug resistance

Indexed keywords

ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; TUMOR PROTEIN;

CANCER STEM CELL; CHEMISTRY; GENE; GENETIC POLYMORPHISM; GENETICS; HUMAN; METABOLISM; MULTIDRUG RESISTANCE; REVIEW;

ATP-BINDING CASSETTE TRANSPORTERS; DRUG RESISTANCE, MULTIPLE; GENES, MDR; HUMANS; NEOPLASM PROTEINS; NEOPLASTIC STEM CELLS; POLYMORPHISM, GENETIC;

EID: 34548619560     PISSN: 16727347     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (96)

1. Zhang J T. Use of arrays to investigate the contribution of ATP-hinding cassette transporters to drug resistance in cancer chemotherapy and prediction of chemosensitivity[J]. Cell Res, 2007, 17 (4): 311-323.
2. Dean M, Rzhetsky A, Allikmets R. Human and Drosophila ABC Proteins//Holland IB, Cole SP, Kuchler K, et al. ABC Proteins, from Bacteria to Man [M]. Amsterdam : Academic Press, 2003: 47-61.
3. Han B, Zhang J. Multidrug resistance in cancer chemotherapy and xenobiotic protection mediated by the half ATP-binding cassette transporter ABCG2[J]. Curr Med Chem Anti-Cane Agents, 2004, 4(1): 31-42.
4. Juliano R, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants [J]. Biochim Biophys Acta, 1976, 455(1): 152-162.
5. Doyle L A, Yang W, Abruzzo L V, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells [J]. Proc Natl Acad Sci USA, 1998, 95(26): 15665-15670.
6. Allikmets R, Schriml L M, Hutchinson A, et al. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance [J]. Cancer Res, 1998, 58(23): 5337-5339.
7. Miyake K, Mickley L, Litman T, et al. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells : demonstration of homology to ABC transport genes [J]. Cancer Res, 1999, 59(1): 8-13.
8. Li Y F, Polgar O, Okada M, et al. Towards understanding the mechanism of action of the multidrug resistance-linked half-ABC transporter ABCG2: a molecular modeling study [J]. J Mol Graph Model, 2007, 25(6): 837-851.
9. Dawson R J, Locher K P. Structure of a bacterial multidrug ABC transporter[J]. Nature, 2006, 443(7108): 180-185.
10. Chang G, Roth C B, Reyes C L, et al. Retraction[J]. Science, 2006, 314(5807): 1875.
11. Graf G A, Li W P, Gerard R D, et al. Coexpression of ATP-binding cassette proteins ABCG5 and ABCG8 permits their transport to the apical surface[J]. J Clin Invest, 2002, 110(5): 659-669.
12. Kage K, Tsukahara S, Sugiyama T, et al. Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization[J]. Int J Cancer, 2002, 97(5): 626-630.
13. Ozvegy C, Litman T, Szakacs G, et al. Functional characterization of the human multidrug transporter, ABCG2, expressed in insect Cells[J]. Biochem Biophys Res Commun, 2001, 285 (1): 111-117.
14. Ozvegy C, Varadi A, Sarkadi B. Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter. Modulation of substrate specificity by a point mutation[J]. J Biol Chem, 2002, 277(50): 47980-47990.
15. Janvilisri T, Venter H, Shahi S, et al. Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis[J]. J Biol Chem, 2003, 278(23): 20645-20651.
16. Litman T, Jensen U, Hansen A, et al. Use of peptide antibodies to probe for the mitoxantrone resistance-associated protein MXR/BCRP/ABCP/ABCG2 [J]. Biochim Biophys Acta, 2002, 1565 (1): 6-16.
17. Xu J, Liu Y, Yang Y, et al. Characterization of oligomeric human half-ABC transporter ATP-binding cassette G2[J]. J Biol Chem, 2004, 279(19): 19781-19789.
18. McDevitt C A, Collins R F, Conway M, et al. Purification and 3D structural analysis of oligomeric human multidrug transporter ABCG2[J]. Structure, 2006, 14(11): 1623-1632.
19. Bhatia A, Schafer H J, Hrycyna C A. Oligomerization of the human ABC transporter ABCG2: evaluation of the native protein and chimeric dimers[J]. Biochemistry, 2005, 44(32): 10893-10904.
20. Henriksen U, Fog J U, Litman T, et al. Identification of intra- and intermolecular disulfide bridges in the multidrug resistance transporter ABCG2[J]. J Biol Chem, 2005, 280(44): 36926-36934.
21. Mitomo H, Kato R, Ito A, et al. A functional study on polymorphism of the ATP-binding cassette transporter ABCG2: critical role of arginine-482 in methotrexate transport [J]. Biochem J, 2003, 373(Pt 3): 767-774.
22. Xu J, Peng H, Chen Q, et al. Oligomerization domain of the multidrug resistance-associated transporter ABCG2 and its dominant inhibitory activity[J]. Cancer Res, 2007, 67(9): 4373-4381.
23. Honjo Y, Hrycyna C A, Yan Q W, et al. Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells [J]. Cancer Res, 2001, 61 (18): 6635-6639.
24. Alqawi O, Bates S, Georges E. Arginino482 to threonine mutation in the breast cancer resistance protein ABCG2 inhibits rhodamine 123 transport while increasing bindings[J]. Biochem J, 2004, 382 (Pt 2): 711-716.
25. Ejendal K F, Diop N K, Schweiger L C, et al. The nature of amino acid 482 of human ABCG2 affects substrate transport and ATP hydrolysis but not substrate binding [J]. Protein Sci, 2006, 15 (7): 1597-1607.
26. HonjoY, Morisaki K, Huff L M, et al. Single-nucleotide polymorphism (SNP) analysis in the ABC half-transporter ABCG2 (MXR/BCRP/ABCP1) [J]. Cancer Biol Ther, 2002, 1 (6): 696-702.
27. Backstrom G, Taipalensuu J, Melhus H, et al. Genetic variation in the ATP-binding cassette transporter gene ABCG2 (BCRP) in a Swedish population[J]. Eur J Pharm Sci, 2003, 18(5): 359-364.
28. Bosch T M, Kjellberg L M, Bouwers A, et al. Detection of single nucleotide polymorphisms in the ABCG2 gene in a Dutch population [J]. Am J Pharmacogenomics 2005, 5(2): 123-131.
29. Yanase K, Tsukahara S, Mitsuhashi J, et al. Functional SNPs of the breast cancer resistance protein-therapeutic effects and inhibitor development[J]. Cancer Lett, 2006, 234(1): 73-80.
30. Tamura A, Watanabe M, Saito H, et al. Functional validation of the genetic polymorphisms of human ATP-binding cassette (ABC) transporter ABCG2: identification of alleles that are defective in porphyrin transport[J]. Mol Pharmacol, 2006, 70(1): 287-296.
31. Denning G M, Anderson M P, Amara J F, et al. Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive[J]. Nature, 1992, 358(6389): 761-764.
32. Kanzaki A, Toi M, Nakayama K, et al. Expression of multidrug resistance-related transporters in human breast carcinoma [J]. Jpn J Cancer Res, 2001, 92(4): 452-458.
33. Nakayama K, Kanzaki A, Ogawa K, et al. Copper-transporting P-type adenosine triphosphatase (ATP7B) as a cisplatin based chemoresistance marker in ovarian carcinoma: comparative analysis with expression of MDR1, MRP1, MRP2, LRP and BCRP[J]. Int J Cancer, 2002, 101(5): 488-495.
34. Diestra J E, Condom E, Del Muro X G, et al. Expression of multidrug resistance proteins P-glyeoprotein, multidrug resistance protein 1, breast cancer resistance protein and lung resistance related protein in locally advanced bladder cancer treated with neoadjuvant chemotherapy: biological and clinical implications [J]. J Urol, 2003, 170(4Pt 1): 1383-1387.
35. Burger H, Foekens J A, Look M P, et al. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response[J]. Clin Cancer Res, 2003, 9(2): 827-836.
36. Yoh K, Ishii G, Yokose T, et al. Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer[J]. Clin Cancer Res, 2004, 10 (5): 1691-1697.
37. Sauerbrey A, Sell W, Steinbach D, et al. Expression of the BCRP gene (ABCG2/MXR/ABCP) in childhood acute lymphoblastic leukaemia[J]. Br J Haematol, 2002, 118(1): 147-150.
38. Steinbach D, Sell W, Voigt A, et al. BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia[J]. Leukemia, 2002, 16(8): 1443-1447.
39. van der Pol M A, Broxterman H J, Pater J M, et al. Function of the ABC transporters, P-glycoprotein, multidrug resistance protein and breast cancer resistance protein, in minimal residual disease in acute myeloid leukemia[J]. Haematologica, 2003, 88 (2): 134-147.
40. Benderra Z, Faussat A M, Sayada L, et al. Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid loukemias[J]. Clin Cancer Res, 2004, 10(23): 7896-7902.
41. Suvannasankha A, Minderman H, O'Loughlin K L, et al. Breast cancer resistance protein (BCRP/MXR/ABCG2) in adult acute lymphoblastic leukaemia: frequent expression and possible correlation with shorter disease-free survival[J]. Br J Haematol, 2004, 127(4): 392-398.
42. Benderra Z, Faussat A M, Sayada L, et al. MRP3, BCRP, and P-glycoprotein activities are prognostic factors in adult acute myeloid leukomia[J]. Clin Cancer Res, 2005, 11(21): 7764-7772.
43. Uggla B, Stahl E, Wagsater D, et al. BCRP mRNA expression v. clinical outcome in 40 adult AML patients[J]. Leuk Res, 2005, 29(2): 141-146.
44. Damiani D, Tiribelli M, Calistri E, et al. The prognostic value of P-glycoprotein (ABCB) and breast cancer resistance protein (ABCG2) in adults with de novo acute myeloid leukemia with normal karyotype[J]. Haematologica, 2006, 91(6): 825-828.
45. Wilson C S, Davidson G S, Martin S B, et al. Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction[J]. Blood, 2006, 108(2): 685-696.
46. van den Heuvel-Eibrink M M, van der Holt B, Burnett A K, et al. CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age[J]. Ann Hematol, 2007, 86(5): 329-337.
47. Zhou S, Sehuetz J D, Bunting K D, et al. The ABC transporter Bcrpl/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype [J]. Nat Med, 2001, 7(9): 1028-1034.
48. Zhou S, Morris J J, Barnes Y, et al. Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo[J]. Proc Natl Acad Sci USA, 2002, 99(19): 12339-12344.
49. Alvi A J, Clayton H, Joshi C, et al. Functional and molecular characterisation of mammary side population cells [J]. Breast Cancer Res, 2003, 5(1): R1-8.
50. Hirschmann-Jax C, Foster A E, Wulf G G, et al. A distinct "side population" of cells with high drug efflux capacity in human tumor Cells[J]. Proc Natl Acad Sci USA, 2004, 101 (39): 14228-14233.
51. - cells in acute myeloid leukemia [J]. Clin Cancer Res, 2005, 11 (6): 2436-2444.
52. Ho M M, Ng A V, Lam S, et al. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells [J]. Cancer Res, 2007, 67 (10): 4827-4833.
53. Haraguchi N, Utsunomiya T, Inoue H, et al. Characterization of a side population of cancer cells from human gastrointestinal system [J]. Stem Cells, 2006, 24(3): 506-513.
54. Chen J S, Pardo F S, Wang-Rodriguez J, et al. EGFR regulates the side population in head and neck squamous cell carcinoma[J]. Laryngoscope, 2006, 116(3): 401-406.
55. Olempska M, Eisenach P A, Ammerpohl O, et al. Detection of tumor stem cell markers in pancreatic carcinoma cell lines [J]. Hepatobiliary Pancreat Dis Int, 2007, 6(1): 92-97.
56. Wang J, Guo L P, Chen L Z, et al. Identification of cancer stem cell-like side population cells in human nasopharyngeal carcinoma cell line[J]. Cancer Res, 2007, 67(8): 3716-3724.
57. Seigel C M, Campbell L M, Narayan M, et al. Cancer stem cell characteristics in retinoblastoma[J]. Mol Vis, 2005, 11: 729-737.
58. Mohan A, Kandalam M, Ramkumar H L, et al. Stem cell markers: ABCG2 and MCM2 expression in retinoblastoma[J]. Br J Ophthalmol, 2006, 90(7): 889-893.
59. Clayton H, Titley I, Vivanco M. Growth and differentiation of progenitor/stem cells derived from the human mammary gland [J]. Exp Cell Res, 2004, 297(2): 444-460.
60. Summer H, Kotton D N, Sun X, et al. Side population cells and Berpl expression in lung [J]. Am J Physiol Lung Cell Mol Physiol, 2003, 285(1): 197-104.
61. Chen Y N, Mickley L A, Schwartz A M, et al. Characterization of adriamycin-resistant human breast cancer cells which display over-expression of a novel resistance-related membrane protein [J]. J Biol Chem, 1990, 265(17): 10073-10080.
62. Hazlehurst L A, Foley N E, Gleason-Guzman M C, et al. Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line [J]. Cancer Res, 1999, 59 (5): 1021-1028.
63. Rabindran S K, Ross D D, Doyle L A, et al. Fumitremorgin C reverses multidrug resistance in cells transfocted with the breast cancer resistance protein[J]. Cancer Res, 2000, 60(1): 47-50.
64. Volk E L, Farley K M, Wu Y, et al. Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance [J]. Cancer Res, 2002, 62(17): 5035-5040.
65. Volk E L, Schneider E. Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter[J]. Cancer Res, 2003, 63(17): 5538-5543.
66. Maliepaard M, van Gastelen M A, de Jong L A, et al. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line[J]. Cancer Res, 1999, 59(18): 4559-4563.
67. Litman T, Brangi M, Hudson E, et al. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2) [J]. J Cell Sci, 2000, 113 (Pt 11): 2011-2021.
68. Nakatomi K, Yoshikawa M, Oka M, et al. Transport of 7-ethyl-10- hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells [J]. Biochem Biophys Res Commun, 2001, 288(4): 827-832.
69. Kawabata S, Oka M, Shiozawa K, et al. Breast cancer resistance protein directly confers SN-38 resistance of lung cancer Cells[J]. Biochem Biophys Res Commun, 2001, 280(5): 1216-1223.
70. Robey R W, Medina-Perez W Y, Nishiyama K, et al. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells [J]. Clin Cancer Res, 2001, 7(1): 145-152.
71. Burger H, van Tol H, Boersma A W, et al. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump [J]. Blood, 2004, 104 (9), 2940-2942.
72. Erlichman C, Boerner S A, Hallgren C G, et al. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux[J]. Cancer Res, 2001, 61 (2): 739-748.
73. Allen J D, Van Dort S C, Buitelaar M, et al. Mouse breast cancer resistance protein (Bcrpl/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein[J]. Cancer Res, 2003, 63(6): 1339-1344.
74. Minderman H, O' Loughlin K L, Pendyala L, et al. VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein [J]. Clin Cancer Res, 2004, 10(5): 1826-1834.
75. Minderman H, Brooks T A, O'Loughlin K L, et al. Broad-spectrum modulation of ATP-binding cassette transport proteins by the taxane derivatives ortataxel (IDN-5109, BAY 59-8862) and tRA96023[J]. Cancer Chemother Pharmacol, 2004, 53(5): 363-369.
76. Robey R W, Steadman K, Polgar O, et al. Pheophorbide a is a specific probe for ABCG2 function and inhibition [J]. Cancer Res, 2004, 64(4): 1242-1246.
77. Allen J D, Brinkhuis R F, Wijnholds J, et al. The mouse Bcrp1/Mxr/Abcp gene : amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin [J]. Cancer Res, 1999, 59(17): 4237-4241.
78. de Bruin M, Miyake K, Litman T, et al. Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR [J]. Cancer Lett, 1999, 146(2): 117-126.
79. Rabindran S K, He H, Singh M, et al. Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C[J]. Cancer Res, 1998, 58(24): 5850-5858.
80. Allen J D, Schinkel A H. Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2)[J]. Mol Cancer Ther, 2002, 1 (6): 427-434.
81. Imai Y, Tsukahara S, Asada S, et al. Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance[J]. Cancer Res, 2004, 64(12): 4346-4352.
82. Zhang S, Yang X, Morris M E. Flavonoids are inhibitors of breast cancer resistance protein (ABCG2) -mediated transport [J]. Mol Pharmacol, 2004, 65(5): 1208-1216.
83. Cooray H C, Janvilisri T, van Veen H W, et al. Interaction of the breast cancer resistance protein with plant polyphenols [J]. Biochem Biophys Res Commun, 2004, 317(1): 269-275.
84. Zhang S, Yang X, Coburn R A, et al. Structure activity relationships and quantitative structure activity relationships for the flavonoid- mediated inhibition of breast cancer resistance protein [J]. Biochem Pharmacol, 2005, 70(4): 627-639.
85. Ahmed-Belkacem A, Pozza A, Munoz-Martinez F, et al. Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2[J]. Cancer Res, 2005, 65(11): 4852-4860.
86. Jin J, Shahi S, Kang H K, et al. Metabolites of ginsenosides as novel BCRP inhibitors [J]. Biochem Biophys Res Commun, 2006, 345 (4): 1308-1314.
87. Chearwae W, Shukla S, Limtrakul P, et al. Modulation of the function of the multidrug resistance-linked ATP-binding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin[J]. Mol Cancer Ther 2006, 5 (8): 1995-2006.
88. Sugimoto Y, Tsukahara S, Imai Y, et al. Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists[J]. Mol Cancer Ther, 2003, 2(1): 105-112.
89. Ozvegy-Laczka C, Hegedus T, Varady G, et al. High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter[J], Mol Pharmacol, 2004, 65(6): 1485-1495.
90. Houghton P J, Germain G S, Harwood F C, et al. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro[J]. Cancer Res, 2004, 64(7): 2333-2337.
91. Maliepaard M, van Gastelen M A, Tohgo A, et al. Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918[J]. Clin Cancer Res, 2001, 7(4): 935-941.
92. Ishii M, Iwahana M, Mitsui I, et al. Growth inhibitory effect of a new camptothecin analog, DX-8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell line PC-6[J]. Anticancer Drugs, 2000, 11(5): 353-362.
93. Rajendra R, Gounder M K, Saleem A, et al. Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin [J]. Cancer Res, 2003, 63(12): 3228-3233.
94. Kruijtzer C M, Beijnen J H, Rosing H, et al. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918[J]. J Clin Oncol, 2002, 20(13): 2943-2950.
95. Jonker J W, Smit J W, Brinkhuis R F, et al. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan[J]. J Natl Cancer Inst, 2000, 92(20): 1651-1656.
96. van Loevezijn A, Allen J D, Schinkel A H, et al. Inhibition of BCRP-mediated drug efflux by fumitremorgin-type indolyl diketopiperazines[J]. Bioorg Med Chem Lett, 2001, 11(1): 29-32.